Oncology-New York最新文献

Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies. 拓展 T 细胞淋巴瘤治疗的视野：关注个性化治疗策略。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-03-03 DOI: 10.46883/2025.25921036

Viviana Cortlana, Jade Gambill, Jenna Ghazal, Kennedy Itodo, Shreevikaa Kannan, Yan Leyfman, Chandler H Park

{"title":"Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies.","authors":"Viviana Cortlana, Jade Gambill, Jenna Ghazal, Kennedy Itodo, Shreevikaa Kannan, Yan Leyfman, Chandler H Park","doi":"10.46883/2025.25921036","DOIUrl":"10.46883/2025.25921036","url":null,"abstract":"T-cell lymphoma, a form of non-Hodgkin lymphoma, presents significant treatment challenges due to its diverse subtypes and aggressive progression. Jasmine Zain, MD, drawing on her expertise in chimeric antigen receptors (CAR) T-cell therapies, is focused on expanding therapeutic options for T-cell lymphomas, particularly peripheral T-cell lymphoma (PTCL). A critical aspect of treatment development involves recognizing that the subtypes of nodal PTCL are defined by specific genetic pathways, which determine their response to different therapies. This insight has led to the development of more personalized, subtype-specific treatment strategies. Current treatment approaches for PTCL typically involve combinations of chemotherapy, targeted therapies, immunotherapy, and stem cell transplantation. The standard first-line therapy, CHOP (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone), has relatively low response rates, highlighting the need for more effective alternatives. While stem cell transplantation is beneficial for certain PTCL subtypes, overall outcomes remain inconsistent. Some targeted therapies have shown efficacy in specific subtypes, but many forms of PTCL are still resistant to available treatments, underscoring the need for further research. In cases of relapsed/refractory disease, stem cell transplantation remains the primary treatment option, though it is associated with significant risks and often impacts patients' quality of life. There is a pressing need for new, less toxic therapies. Several targeted drugs are currently in clinical trials, with the goal of improving treatment options for patients with relapsed/refractory PTCL. Ongoing research into the genetic and molecular characteristics of PTCL aims to develop more individualized therapies that are better suited to each patient's specific disease profile, offering hope for improved outcomes in this challenging lymphoma subtype.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"39 2","pages":"80-84"},"PeriodicalIF":1.8,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Updates in Surgical Management of the Axilla.

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-03-03 DOI: 10.46883/2025.25921035

Anita Mamtani, Andrea V Barrio

{"title":"Updates in Surgical Management of the Axilla.","authors":"Anita Mamtani, Andrea V Barrio","doi":"10.46883/2025.25921035","DOIUrl":"10.46883/2025.25921035","url":null,"abstract":"Over the past 3 decades, axillary management in patients with breast cancer has evolved dramatically. The introduction and increasing use of sentinel lymph node biopsy (SLNB) have revolutionized the surgical approach for many patients with early breast cancer, permitting appropriate axillary staging without compromising prognosis and conferring significantly less morbidity than axillary lymph node dissection (ALND). For patients with clinically node-negative breast cancer and pathologically negative nodes or limited nodal metastases who have up-front surgery followed by radiotherapy, SLNB alone is now the standard of care, as it is for many patients who are clinically node positive and achieve a nodal pathologic complete response to neoadjuvant therapy. Omission of SLNB is also becoming possible for many patients with early-stage hormone receptor-positive/HER2-negative clinically node-negative breast cancer, with a large randomized trial demonstrating noninferiority of omission of axillary surgery to SLNB. Conversely, for those with residual nodal disease after neoadjuvant chemotherapy or those with a clinically positive axilla who have up-front surgery, ALND remains indicated, although clinical trials evaluating de-escalation of axillary surgery in these patient subsets are ongoing. As multidisciplinary treatment paradigms become increasingly nuanced, it is crucial that systemic therapy treatment decisions for patients with early-stage breast cancer be based on the available pathologic nodal status provided by SLNB, without the need for ALND to find additional positive nodes. Here we review recent advances and ongoing controversies in the modern surgical management of the axilla in breast cancer.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"39 2","pages":"70-75"},"PeriodicalIF":1.8,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Potential for Improved Processes, Outcomes, and Economics of Health Care.

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-02-04 DOI: 10.46883/2025.25921034

Nora Janjan Md Mpsa Mba

引用次数: 0

Insights, Knowledge Gaps, and Priorities in Marginal Zone Lymphoma Research.

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-02-04 DOI: 10.46883/2025.25921033

Lymphoma Research Foundation Lymphoma Research Foundation

{"title":"Insights, Knowledge Gaps, and Priorities in Marginal Zone Lymphoma Research.","authors":"Lymphoma Research Foundation Lymphoma Research Foundation","doi":"10.46883/2025.25921033","DOIUrl":"https://doi.org/10.46883/2025.25921033","url":null,"abstract":"Marginal zone lymphoma (MZL) is a rare, indolent form of non-Hodgkin lymphoma that arises from B cells in the marginal zone of lymphoid tissues. MZL comprises 3 key subtypes: extranodal, nodal, and splenic MZL. Despite being generally slow growing, MZL presents significant challenges due to its heterogeneous nature, inconsistently defined disease, and the limited efficacy and availability of current treatments. Advancements in targeted therapies and a deeper understanding of the molecular underpinnings of MZL are critical to improving patient outcomes and achieving more durable remissions. At the Lymphoma Research Foundation's 2024 Marginal Zone Lymphoma Virtual Scientific Workshop, researchers gathered to discuss recent developments in both basic scientific and clinical research so that together we can continue to develop our understanding of MZL and improve outcomes for patients. This report, which includes a summary of each presentation, aims to review the findings presented at the workshop. Additionally, it highlights opportunities, reviews questions, and assesses areas for future study to set the stage for treatment advancements in the coming decades.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"1 null","pages":"11-32"},"PeriodicalIF":1.8,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143505897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials. 转移性非小细胞肺癌临床试验外治疗的临床试验资格和结果

IF 1.8 4区医学

Oncology-New York Pub Date : 2024-12-03 DOI: 10.46883/2024.25921032

Clayton K Oakley, Amulya Yellala, Sunil Tulpule, Robin High, Apar Kishor Ganti, Alissa S Marr

{"title":"Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials.","authors":"Clayton K Oakley, Amulya Yellala, Sunil Tulpule, Robin High, Apar Kishor Ganti, Alissa S Marr","doi":"10.46883/2024.25921032","DOIUrl":"10.46883/2024.25921032","url":null,"abstract":"Introduction: There are limited data available regarding patient outcomes in those who would have been ineligible to receive therapy based on the original clinical trial eligibility criteria. We decided to conduct a retrospective study to evaluate outcomes based on clinical trial eligibility in patients with metastatic non-small cell lung cancer (NSCLC).Methods: A retrospective chart review of all patients with metastatic NSCLC who received first-line systemic therapy at a single academic institution was performed. Each patient's chart was reviewed to determine if they would have qualified for the phase 3 clinical trial that led to the approval of the specific treatment regimen which they received. Data were analyzed to determine if there was a difference in survival time between those who would have been eligible compared with those who were ineligible for the clinical trial of the treatment regimen administered.Results: There were 170 patients with a diagnosis of metastatic NSCLC who received first-line systemic therapy. Of these, 109 received combined chemotherapy, 25 received immunotherapy, and 36 received targeted therapy. There is a statistically significant difference in the restricted mean survival time between the eligible and ineligible groups in those who received combined chemotherapy (19.9 months vs 13.2 months; P = .03), but not in either the immunotherapy group (22.4 months vs 12.9 months; P = .06) or the targeted therapy group (57.7 months vs 39.0 months; P = .14).Conclusion: These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"38 12","pages":"462-468"},"PeriodicalIF":1.8,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142856531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and Safety of Zolbetuximab in Gastric Cancer. 唑仑妥昔单抗治疗胃癌的疗效和安全性。

IF 1.8 4区医学

Oncology-New York Pub Date : 2024-12-03 DOI: 10.46883/2024.25921031

Aiman Waheed, Muhammad Numan Saleem, Yash Shah, Muhammad Hamza Gul, Helai Hussaini, Abdul Baseer Wardak

引用次数: 0

Implementing a Multidisciplinary Lifestyle Medicine Clinic for Cancer Survivorship. 为癌症幸存者开设多学科生活方式医学诊所。

IF 1.8 4区医学

Oncology-New York Pub Date : 2024-11-05 DOI: 10.46883/2024.25921030

Rachel A Millstein, Loren Winters, Carol Sullivan, Stephanie Eisenstat, Emily Sorg, Amy Comander

{"title":"Implementing a Multidisciplinary Lifestyle Medicine Clinic for Cancer Survivorship.","authors":"Rachel A Millstein, Loren Winters, Carol Sullivan, Stephanie Eisenstat, Emily Sorg, Amy Comander","doi":"10.46883/2024.25921030","DOIUrl":"10.46883/2024.25921030","url":null,"abstract":"Background: Lifestyle medicine (LM) is increasingly recognized in cancer survivorship guidelines. The 6 LM pillars are physical activity, a predominantly plant diet, restorative sleep, stress management, avoiding risky substance use, and social connections. Through a multidisciplinary LM clinic in oncology, we describe 2 illustrative cases and the implications for broader implementation and dissemination of this clinic model.Methods: In the multidisciplinary LM clinic in oncology, patients meet with an American College of Lifestyle Medicine (ACLM) board-certified physician or nurse practitioner, a registered dietitian, and, as needed, a clinical psychologist, a psychiatrist, an obesity medicine physician, a physical therapist, and/or a rehabilitation medicine physician.Results: Patient 1 met with the physician, the registered dietitian, the psychologist, and an affiliated cancer center psychiatrist. Patient 2 met with the nurse practitioner and the registered dietitian. The 2 cases presented illustrate the diversity of LM pillars and strategies to increase health and well-being post cancer treatment.Conclusion: This paper details the model of implementation of a novel oncology-focused multidisciplinary LM clinic and the clinical focuses of 2 diverse patients. The LM needs of cancer survivors seeking lifestyle consultation are growing, and awareness of the benefits of LM for this population can enhance the quality of life for patients who are survivors of cancer.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"38 11","pages":"421-425"},"PeriodicalIF":1.8,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment? 广撒网：177Lu-Dotatate 治疗的最佳时机是什么时候？

IF 1.8 4区医学

Oncology-New York Pub Date : 2024-11-05 DOI: 10.46883/2024.25921029

Natasha Bahri, Christiana Crook, Daneng Li

引用次数: 0

The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion. 隐藏的危险揭开多发性骨髓瘤与胸腔积液之间的联系

IF 1.8 4区医学

Oncology-New York Pub Date : 2024-11-05 DOI: 10.46883/2024.25921028

Fnu Fatima, Faryal Arif, Muhammad Hamza Gul, Neha Siddiqui, Muhammad Zulqarnain, Abdul Baseer Wardak

引用次数: 0

Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors. 遗传性肾肿瘤综合征与 mTOR 抑制剂的使用。

IF 1.8 4区医学

Oncology-New York Pub Date : 2024-10-17 DOI: 10.46883/2024.25921027

José Luis Rodríguez-Olivares, Héctor Raúl González-Sánchez, Evelyn Lilian Beas-Lozano, Jazmin Arteaga-Vázquez, Elaine T Lam Md, María T Bourlon

{"title":"Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors.","authors":"José Luis Rodríguez-Olivares, Héctor Raúl González-Sánchez, Evelyn Lilian Beas-Lozano, Jazmin Arteaga-Vázquez, Elaine T Lam Md, María T Bourlon","doi":"10.46883/2024.25921027","DOIUrl":"10.46883/2024.25921027","url":null,"abstract":"The Case A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%. A chest CT scan revealed pulmonary cystic lesions consistent with lymphangioleiomyomatosis and a right spontaneous pneumothorax, which resolved with the placement of a chest tube. Physical examination revealed a hypopigmented macule on the skin of the lumbar region, facial angiofibromas, and periungual fibromas. An abdominal MRI documented multiple bilateral renal tumors that were hypointense on T2-weighted imaging and showed a black boundary artifact, suggestive of fat-poor angiomyolipomas (AMLs). Subsequent percutaneous biopsy of the largest renal tumor confirmed the diagnosis of angiomyolipoma (positive for HMB-45 on immunohistochemistry). The brain MRI revealed subependymal nodules. The pulmonary function tests showed a mild obstructive pattern. Germline genetic testing confirmed the suspected diagnosis, and the patient started oral systemic treatment with everolimus (Afinitor) 10 mg once daily, along with dexamethasone rinses for prophylaxis.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"38 10","pages":"376-380"},"PeriodicalIF":1.8,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0